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Introduction: The assessment of the activity of rheumatoid arthritis and juvenile idiopathic
arthritis is made by means of the tools DAS-28 and JADAS, respectively.
Objective: To compare DAS-28 and JADAS with scores of 71, 27 and 10 joint counts in juvenile
idiopathic arthritis.
Method: A secondary analysis of a phase III placebo-controlled trial, testing safety and efﬁ-
cacy  of abatacept was conducted in 8 patients with 178 assessment visits. Joint count scores
for  active and limited joints, physician’s and parents’ global assessment by 0–10 cm Visual
Analog Scale, and erythrocyte sedimentation rate normalized to 0–10 scale, in all visits. The
comparison among the activity indices in different observations was made through Anova
or  adjusted gamma model. The paired observations between DAS-28 and JADAS 71, 27 and
10,  respectively, were analyzed by linear regression.
Results: There were signiﬁcant differences among individual measures, except for ESR, in
the  ﬁrst 4 months of biological treatment, when ﬁve of the eight patients reached ACR-
Pedi  30, with improvement. The indices of DAS-28, JADAS 71, 27 and 10 also showed
signiﬁcant difference during follow-up. Linear regression adjusted model between DAS-
28  and JADAS resulted in mathematical formulas for conversion: [DAS-28 = 0.0709 (JADAS
71) + 1.267] (R2 = 0.49); [DAS-28 = 0.084 (JADAS 27) + 1.7404] (R2 = 0.47) and [DAS-28 = 0.1129
(JADAS-10) + 1.5748] (R2 = 0.50).
Conclusion: The conversion of scores of DAS-28 and JADAS 71, 27 and 10 for this mathematicalmodel would allow equivalent application of both in adolescents with arthritis.
© 2014 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail: claudi@fmb.unesp.br (C.S. Magalhães).
ttp://dx.doi.org/10.1016/j.rbre.2014.08.009
255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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Comparac¸ão  entre  o  Disease  Activity  Score  e  o  Juvenile  Arthritis  Disease
Activity  Score  na  artrite  idiopática  juvenil
Palavras-chave:
Artrite idiopática juvenil
Artrite reumatoide
Disease Activity Score-28
Juvenile Arthritis Disease
Activity Score
r  e  s  u  m  o
Introduc¸ão: A avaliac¸ão de atividade da artrite reumatoide e da artrite idiopática juvenil é
feita por meio de instrumentos distintos, respectivamente pelo DAS-28 e pelo JADAS.
Objetivo: Comparar o DAS-28 e o JADAS com a pontuac¸ão de 71, 27 e 10 articulac¸ões, na
artrite idiopática juvenil.
Método: Foram avaliadas 178 visitas em oito pacientes com artrite idiopática juvenil, par-
ticipantes de um ensaio clínico controlado de fase III, testando eﬁcácia e seguranc¸a do
abatacepte. Pontuaram-se as articulac¸ões ativas e limitadas, a avaliac¸ão global pelo médico
e  pelos pais em escala analógica visual de 0-10 cm e a velocidade de hemossedimentac¸ão
convertida em escala de 0-10, em todas as visitas. A comparac¸ão entre os índices de ativi-
dade  entre diferentes observac¸ões foi por Anova ou modelo ajustado Gama. As observac¸ões
pareadas entre o DAS-28 e o JADAS 71, 27 e 10, respectivamente, foram analisadas por meio
de  regressão linear.
Resultados: Houve diferenc¸a signiﬁcativa entre as medidas individuais, exceto a VHS, nos
primeiros quatro meses de tratamento com biológico, quando cinco entre os oito pacientes
atingiram a resposta ACR-Pedi 30, com melhoria. Os índices DAS-28, JADAS 71, 27 e 10 tam-
bém  apresentaram diferenc¸a relevante durante o período de observac¸ão. O ajustamento por
meio de regressão linear entre o DAS-28 e o JADAS resultou em fórmulas matemáticas para
conversão: [DAS-28 = 0,0709 (JADAS 71) + 1,267] (R2 = 0,49); [DAS-28 = 0,084 (JADAS 27) + 1,7404]
(R2 = 0,47) e [DAS-28 = 0,1129 (JADAS-10) + 1,5748] (R2 = 0,50).
Conclusão: A conversão da pontuac¸ão do DAS-28 e do Jadas 71, 27 e 10 por esse modelo
matemático permitiria a aplicac¸ão equivalente de ambos em adolescentes com artrite.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Juvenile idiopathic arthritis (JIA) has a chronic course and great
variability of outcomes, it may progress to spontaneous remis-
sion or be refractory to available treatments.1 JIA subtypes
represent different phenotypes, classiﬁed as oligoarticular (<5
joints), polyarticular (≥5 joints), systemic, arthritis related to
enthesitis, psoriatic arthritis, and undifferentiated or unclas-
siﬁed arthritis.2
In order to assess arthritis activity, it is essential to measure
the response to treatment, and early treatment is crucial to the
outcome. In children, the response to treatment, evaluated in
clinical trials, involves six primary outcome measures: physi-
cian’s global assessment, global assessment by the parents or
by the patient, joint count in absolute numbers of inﬂamed
joints and joints with limited range of motion, erythrocyte
sedimentation rate (ESR), and functional capacity index. The
minimum criteria for response (ACR Pedi 30) are deﬁned as
improvement of at least 30% in three of six measures, with
not more  than 30% of worsening in no more  than one of these
parameters, representing a cutoff of response differentiation
in the treated group and in the placebo group in clinical trials.3
Currently, the improvements that are considered clinically sig-
niﬁcant are those in excess of 50, 70, 90%, or even the inactive
state of arthritis.4 However, these measures are related to the
response to treatment, and are not suitable as absolute meas-
ures of arthritis activity, because nature of calculation doesnot allow absolute comparison of response between groups of
patients.
The most commonly used in rheumatoid arthritis (RA) are
the DAS5 (Disease Activity Score) and DAS286 in its simpliﬁed
version. JADAS7 (Juvenile Arthritis Disease Activity Score), with
three versions of joint scoring, was developed for JIA. Both
use the same components for the absolute assessment of
arthritis activity, including “active” joint count, physician’s
and patient’s or his/her parents’ global assessment, and labo-
ratory tests, which may be ESR or C-reactive protein (CRP), and
is useful in clinical trials and in daily practice.8
DAS286 combines information on the number of painful
and swollen joints, with 28 joints being selected, as well as
ESR or CRP and patient’s global assessment measured on a
visual analog scale (VAS) from zero to 10 cm.  DAS28 score is
calculated using a mathematical formula, and the activity of
arthritis can be interpreted in categorical scale.
JADAS score7 is performed by adding the four individ-
ual measurements: global assessment of arthritis activity by
the physician, in 10-cm VAS, global evaluation by the par-
ents/patients as measured in the same 10-cm VAS, where 0
indicates no activity and 10, maximum activity, ESR and joint
count. There are three versions, scoring from 0 to 71, 0 to 27
or 0 to 10 joints.Functional capacity is often assessed through a health
questionnaire, the Childhood Health Assessment Question-
naire (CHAQ),9,10 the corresponding version of the Health
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ssessment Questionnaire (HAQ). Both evaluate the degree
f difﬁculty and independence in activities of daily life in
ight domains of functional capacity, also considering the pain
nd discomfort through aggregated VAS (0–10 cm). Functional
apacity is included among the response measures of ACR Pedi
0.
The present study is a secondary analysis of a placebo-
ontrolled, phase III clinical trial, to evaluate the efﬁcacy
nd safety of intravenous abatacept in patients with
ctive polyarticular JIA and unresponsive to treatment with
ntirheumatic therapy with methotrexate (MTX).11,12 Patients
elected for clinical trials have more  intense activity and are
esistant to conventional treatment, showing more  enhanced
ifferences of clinical response. Thus, this sample was con-
idered optimal to compare different continuous measures of
ctivity.
The aim was to explore score equivalence of the tool DAS28
nd JADAS with scores of 71, 27 and 10 joints, respectively, in
hildren and adolescents with JIA.
ubjects  and  method
ne hundred and seventy-eight visits were assessed of eight
atients with JIA who participated in a controlled clinical
hase III trial testing the efﬁcacy and safety of abatacept11,12
nd using the same evaluations at intervals of four to 12 weeks
f the original trial, a withdrawal study design,11,12 which
ncluded an open-label phase of 4 months, double-blind phase
rial open-label extension phase of up to 5 years. In the double-
lind period, assessments were monthly performed, and in
ther periods, complete assessments, including measures of
ctivity, were performed every 3 months. The same clinical,
aboratory and functional parameters of the clinical trial for
he calculation of activity rates of DAS28 and JADAS-71, 27, 10
ere used. The protocol of secondary study was approved by
he Ethics Committee in Institutional Research (no. 345/2009)
f 14 September 2009.
Data were collected from ﬁrst to last visit with complete
oint assessment. Of the eight subjects included, ﬁve com-
leted the open phase of induction and the double-blind
hase, extension open-label phase. Of the ﬁve who concluded
he double-blind period, two were given placebo and three
ere given the study medication. Three subjects concluded
he open period, but were not approved for the double-blind
ince they did not reach ACR-Pedi 30 response, staying in the
pen-label extension indicated by the protocol. Four subjects
eft the study in the extension phase in different periods, due
o lack of medication efﬁcacy, with change of treatment being
ecessary. Three subjects concluded the 5 years of extension
hase.
Standardized joint assessment (it is more  speciﬁc for the
echnical procedure) was performed by the same observer
hroughout the study. Within the same joint assessment of
ach valid visit, JADAS-71, 27 and 10 were scored alongside
AS28. To calculate JADAS 71, the score includes 71 joints, with
ore comprehensive examination including the joints of the
ower and upper extremities, spine, and temporomandibular
oint. In JADAS-27, the following joints are scored: cervi-
al spine, elbows, wrists, metacarpophalangeal from 1 to 3, 0 1 5;5  5(1):31–36 33
proximal interphalangeal, hips, knees and ankles. Regarding
JADAS-10, the upper score is 10, that is, if a patient has 15 or
20 active joints, the maximum score to be assigned will be
10.
JADAS ﬁnal score is calculated by the sum of four compo-
nents: global assessment of arthritis activity by a physician,
measured in a 10-cm VAS, where zero indicates no activity and
10, maximum activity; global assessment by parents/patients
also measured on a 10-cm VAS, where zero indicates no activ-
ity and 10, the maximum activity perceived by parents or
by the patient; active joints count of zero-71 joints and ESR
converted to a scale from zero-10 = [VHS mm/h  − 20)/10] with
values over 120 mm/h  being converted to 120.
The following joints were assessed for scoring DAS 28:
shoulders (2), elbows (2), wrists (2), metacarpophalangeal (10),
proximal interphalangeal (10) and knees (2). The joints with
pain and edema are independently scored, in addition to the
global assessment of activity by the patient, which in this
study was performed either by the parents or by the patient
him/herself, according to age, being measured on a 10-cm VAS
in which zero indicates no disease activity and 10, maximum
activity, according to the patient’s perception. In this study,
scales scores were performed by the parents regardless of age.
DAS28 score was calculated using the following formula in
Microsoft Excel:
DAS28 = 0.56√number of joints with pain(28)
+ 0.28√number of joints with swelling + 0.70 log n(ESR)
+ 0.014 global VAS.
Functional capacity, as an integral parameter for the calcula-
tion of ACR-Pedi-30 response, was assessed by the CHAQ score
with values of zero-3, with 3 meaning the maximum disability
scale.
Statistics  analysis
A descriptive analysis was carried out of baseline variables
obtained during patient selection and with calculation of aver-
age, standard deviation, median and quartiles for quantitative
variables, as well as frequencies and percentages for qualita-
tive variables.
A longitudinal analysis of variables was performed using
a repeated measure model through analysis of variance
(ANOVA) followed by Tukey’s multiple comparisons test for
data showing symmetrical distribution. The adjustment of a
generalized linear model for repeated measures, with Gamma
distribution, was performed for the data that showed an asym-
metric distribution.
For comparative evaluation between DAS28 and JADAS in
three versions (71, 27 and 10), a linear regression was per-
formed by applying the ANOVA test for data with normal
distribution. As for the comparison between JADAS-71, JADAS-
27 and JADAS-10, a model with Gamma  distribution was
adjusted.
All analyses were performed using SAS for Windows, v.9.2.
In all tests, we used a signiﬁcance level of 5% or the corre-
sponding p-value.
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Table 1 – Clinical, anthropometric, laboratorial, activity and functional parameters in eight patients during the ﬁrst
evaluation of selection for the clinical trial.
Variables Average Standard deviation Median Q1 Q3
Age (months) 137.6 39.5 136.2 110.8 162.3
Weight (kg) 31.9 11.4 32.4 23.4 39.4
Height (cm) 135.5 18.6 139.7 124 149.5
No. of active joints 24 10.5 20.5 18 30.5
No. of limited joints 20.3 11.6 16.5 15 26
No. of joints with edema 19.6 10 20 12.5 28
No. of joints with pain 12 13.3 8.5 4.5 11.5
Physician’s VAS (0–10 cm) 5.5 1.3 5.8 5.3  6.3
Parents’ VAS (0–10 cm) 3.6 2.2 3.1 1.8 5.6
Pain VAS (0–10 cm) 3.2 2.1 2.4 2.2 5.3
CHAQ DI (0–3) 1.2 0.5 1.2 0.8 1.8
JADAS-71 (0–101) 10.1 12 6.1 0.4 14.1
JADAS-27 (0–57) 8.7  10 5.7 0.4 11.5
JADAS-10 (0–40) 7.9 7.6 6.1 3.9 13
DAS-28 (0–7.8) 4.8 1 4.8 3.9 5.2
ESR (mm/h) 36.2 10.3 35 30 45
AQ-
R, erQ1, ﬁrst quartile; Q3, third quartile; VAS, visual analogical scale; CH
Juvenile Arthritis Disease Activity Score;  DAS-28, Disease Activity Score;  ES
Results
Three boys and ﬁve girls were assessed, all diagnosed with JIA
and aged 7–17 years, with a case classiﬁed as systemic and
seven as polyarticular, with two being positive for rheumatoid
factor (latex test). Clinical, anthropometric, laboratory and
activity variables of arthritis, including the functional indices
in the ﬁrst evaluation, are presented in Table 1.
With the use of ANOVA a signiﬁcant difference was found
in the visits which took place for selection and those after 4
months of treatment for all indices, when ﬁve patients met  the
criteria of ACR Pedi 30 response, that is, there was improve-
ment in 30% of at least three of the six key variables.
Longitudinal comparison showed that there was asymmet-
ric distribution of CHAQ, DAS28, JADAS-71, 27 and 10 variables,
and the adjustment of the model with Gamma  distribution
showed statistically signiﬁcant difference within the assess-
ments (p < 0.05), with the highest rates being in the ﬁrst and in
the second evaluation, respectively, at the selection and after
4 months of biological treatment in open phase. The other
visits included a total of 30 serial evaluations, monthly, within
6 months of the double-blind phase, and quarterly in the eval-
uations that followed during the open-label extension. These
evaluations were compared, but no signiﬁcant difference was
found in all the individual parameters for the calculation of
the indices and items of DAS28 and JADAS-71, 27 and 10. No
signiﬁcant difference was observed within the respective ver-
sions of JADAS-71, 27 and 10. For this comparison, we also
adjusted a model with Gamma  (p = 0.5) distribution.
The linear regression analysis of JADAS-71, 27 and 10 and
DAS 28 resulted in conversion formulas among the scales, the
regression analysis of which is shown in Fig. 1:
[DAS 28 = 0.0709 (JADAS-71) + 1.267] (R2 = 0.49).[DAS 28 = 0.084 (JADAS-27) + 1.7404] (R2 = 0.47).
[DAS 28 = 0.1129 (JADAS-10) + 1.5748] (R2 = 0.50).DI, Childhood Health Assessment Questionnaire Disability Index;  JADAS,
ythrocyte sedimentation rate.
Discussion
The presented results support the equivalence between the
DAS-28 and JADAS in three versions, with joint counts of 71,
27 or 10, respectively, through longitudinal observation made
during a controlled clinical trial in polyarticular JIA. Besides
DAS28, there are other instruments used for RA, such as the
Clinical Disease Activity Index (CDAI), among others,13 but of
limited use in pediatric patients.
Continuous measures such as DAS28 and JADAS have the
advantage of establishing absolute values, identifying changes
in clinical status by a number on a continuous scale.13 The
straightforward calculation makes the method feasible in
daily practice, just as in clinical trials. However, there are few
publications reporting the use of DAS28 in JIA.7,8
Measures in absolute values provide better consistency of
assessment among physicians and allow patients to under-
stand the signiﬁcance of their disease activity via an absolute
number. The corresponding measures for JIA were recently
developed,7 and three versions of the tool JADAS allowed to
equate the different presentations of JIA according to the ILAR
classiﬁcation.2
One must also consider that the joint counts of the DAS28
omit the lower limb joints,14 but in the JIA the involvement of
the lower extremities is predominant. Measures of perceived
activity of arthritis by the physician, the patient him/herself or
their parents, as well as ESR or CRP, implement the compos-
ite measures, weighing up several competing factors for the
activity status.
In JADAS validation study,7 as well as in a recent study,
which used CRP to replace ESR,15 results of JADAS-71, 27 and
10 kept the correlation among them and with the other activity
parameters. Also, McErlane et al.16 recently calculated JADAS
with only three variables, excluding ESR for broader applica-
bility, and reported a correlation of measures and their metric
equivalence.
One must consider, however, that in this study VAS scores
by the patient him/herself as conceived in DAS28 was replaced
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Fig. 1 – Linear regression plots within values of DAS28 and
JADAS-71 (a), JADAS-27 (b) and JADAS-10 (c) and their
respective conversion equations (plots a, b, c).
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counts invalidate the DAS-28 remission deﬁnition owing toy the score of the scale performed by the parents. It is also
nown that, regardless of age, caregiver’s perception may sub-
tantially differ from the perception of the patient at any age.
Among the other limitations of this analysis we ﬁnd the
mall sample that limits the power of the study, and the selec-
ion of children enrolled in clinical trials. If, on one hand,
he population sample would provide greater variability of
ctivity, strict control of all measures and standardized joint
xamination, by the same observer at regular intervals, in
ddition to the parallel evaluation of response measures (ACR-
edi-30) to establish responders, the response pattern in the
eriod of greatest activity when selecting for testing, were the
avorable points to test this equivalence.17
There is practical applicability of the results to patients
ith JIA, because, besides the simple and direct score, the indi-
idual measures of clinical parameters can be conducted in
aily practice. The use of metric conversion may also be use-
ul in speciﬁc situations of transition from adolescent to adult
ondition. As an example, a patient diagnosed with JIA at 15 0 1 5;5  5(1):31–36 35
years and another diagnosed with RA at 17 could be evaluated
by calculating the equivalence of the instruments used.
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